Predictive Oncology Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement
February 02 2021 - 12:00PM
Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or
“the Company”), a knowledge-driven company focused on applying
artificial intelligence (“AI”) to personalized medicine and drug
discovery, today announced that based on a notification letter
recently received from the Listing Qualifications Department of the
Nasdaq Stock Market Inc. (the “Nasdaq”), the Company has regained
compliance with the minimum bid price requirement set forth in Rule
5550(a)(2) of the Nasdaq Listing Rules (the “Minimum Bid Price
Requirement”).
The Company had previously received written notice from Nasdaq
in October 2020 indicating that because the closing bid price per
share had been below $1.00 for a period of 30 consecutive business
days and that the Company did not meet the Minimum Price Bid
Requirement. According to the recent notification letter, the staff
of Nasdaq has determined that for the last 10 consecutive business
days, from January 19, 2021 to February 1, 2021, the closing bid
price of the Company’s common stock has been at $1.00 per share or
greater, and the Company has regained compliance with the Minimum
Bid Price Requirement, and the matter is now closed.
About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates through three
segments (Skyline, Helomics and Soluble Biotech), which contain
four subsidiaries: Helomics, TumorGenesis, Skyline Medical and
Soluble Biotech.
Helomics applies artificial intelligence to its rich data
gathered from patient tumors to both personalize cancer therapies
for patients and drive the development of new targeted therapies in
collaborations with pharmaceutical companies. TumorGenesis Inc.
specializes in media that help cancer cells grow and retain their
DNA/RNA and proteomic signatures, providing researchers with a tool
to expand and study cancer cell types found in tumors of the blood
and organ systems of all mammals, including humans. Skyline Medical
markets its patented and FDA cleared STREAMWAY System, which
automates the collection, measurement and disposal of waste fluid,
including blood, irrigation fluid and others, within a medical
facility, through both domestic and international divisions.
Soluble Biotech is a provider of soluble and stable formulations
for proteins including vaccines, antibodies, large and small
proteins and protein complexes. For more information, please
visit www.predictive-oncology.com.
Forward-looking Statements
Certain of the matters discussed in this press release contain
forward-looking statements that involve material risks to and
uncertainties in the Company’s business that may cause actual
results to differ materially from those anticipated by the
statements made herein. Such risks and uncertainties include:
market and other conditions and the intended use of net proceeds
from the registered direct offering, a variety of other risks and
uncertainties including, among other things, factors discussed
under the heading “Risk Factors” in our filings with the SEC.
Except as expressly required by law, the Company disclaims any
intent or obligation to update these forward-looking
statements.
Investor Relations Contact:
Landon CapitalKeith Pinder(404)
995-6671kpinder@landoncapital.net
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Apr 2023 to Apr 2024